Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. FCF margin (%)

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndFCF margin (%) YoY (%)
Dec 31, 202446.1+2.48%
Dec 31, 202345+26.28%
Dec 31, 202235.6-46.97%
Dec 31, 202167.2+239.70%
Dec 31, 202019.8-143.35%
Dec 31, 2019-45.6+27.98%
Dec 31, 2018-35.7-185.09%
Dec 31, 201741.9-214.88%
Dec 31, 2016-36.5+24.93%
Dec 31, 2015-29.2-55.00%
Dec 31, 2014-64.9-31.13%
Dec 31, 2013-94.2-39.33%
Dec 31, 2012-155.3+147.64%
Dec 31, 2011-62.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat